Segall Bryant & Hamill LLC Trims Stock Position in Insmed Incorporated (NASDAQ:INSM)

Segall Bryant & Hamill LLC trimmed its stake in shares of Insmed Incorporated (NASDAQ:INSM) by 1.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 139,045 shares of the biopharmaceutical company’s stock after selling 1,870 shares during the quarter. Segall Bryant & Hamill LLC owned about 0.08% of Insmed worth $9,600,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Steward Partners Investment Advisory LLC lifted its holdings in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares during the period. V Square Quantitative Management LLC lifted its stake in shares of Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 248 shares during the period. Spire Wealth Management purchased a new stake in shares of Insmed in the fourth quarter valued at about $47,000. Smartleaf Asset Management LLC boosted its holdings in shares of Insmed by 98.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new position in shares of Insmed during the fourth quarter worth about $86,000.

Analysts Set New Price Targets

A number of brokerages have weighed in on INSM. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $100.00 price objective on shares of Insmed in a report on Wednesday, March 19th. Stifel Nicolaus decreased their price target on Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a research note on Friday, February 21st. HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Insmed in a research report on Friday, February 21st. Morgan Stanley raised their target price on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Finally, Truist Financial upped their price target on shares of Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.00.

Insider Buying and Selling

In other news, CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the sale, the chief executive officer now owns 384,960 shares in the company, valued at $26,885,606.40. This trade represents a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Sara Bonstein sold 18,322 shares of Insmed stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total value of $1,471,439.82. Following the completion of the sale, the chief financial officer now directly owns 118,863 shares of the company’s stock, valued at approximately $9,545,887.53. This represents a 13.36 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 550,957 shares of company stock worth $42,992,528. 4.60% of the stock is owned by insiders.

Insmed Stock Down 2.5 %

Shares of NASDAQ:INSM opened at $76.57 on Thursday. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $13.86 billion, a P/E ratio of -13.70 and a beta of 1.28. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91. The stock’s fifty day simple moving average is $77.97 and its 200-day simple moving average is $73.91.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The firm had revenue of $104.44 million during the quarter, compared to analysts’ expectations of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. As a group, equities research analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.